Business Context and Reporting Period
This Form 8-K is a current report filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on December 14, 2017. The registrant is a Delaware corporation headquartered in Cincinnati, Ohio, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance.
Material Changes
- Leadership Appointment: Stephen Hoffman, M.D., Ph.D., who became Chief Executive Officer on December 1, 2017, was elected as a Class I director on December 14, 2017. He will serve until the 2018 annual meeting of stockholders.
- Compensation Structure: Dr. Hoffman will receive no additional compensation for his director role beyond his existing CEO compensation.
- Equity Plan Approval: The Board approved the Amended and Restated 2017 Employee Stock Purchase Plan (ESPP) for shareholder ratification at the next Annual Meeting.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors. The primary contingency noted is that the ESPP requires shareholder approval to become effective. If approved, the plan reserves 300,000 shares initially, with annual increases starting January 1, 2019, capped at the least of 1% of outstanding shares, 350,000 shares, or a Board-determined amount.
Investor Verification Checklist
- Verify the shareholder vote outcome for the Amended and Restated 2017 Employee Stock Purchase Plan at the 2018 Annual Meeting.
- Confirm the exact terms of the ESPP by reviewing Exhibit 10.1 attached to the filing.
- Monitor the tenure of Dr. Hoffman as both CEO and Director leading up to the 2018 annual meeting.